Business Roundtable
IPOs and Alternative Exit Strategies - Is the glass half full, or half empty?
Monday, February 12, 2007
3:30 PM
Conrad Suite
A year ago, SPACs and reverse mergers had promise as the new "backdoor IPO." What's happened over the past year? Is the London AIM market viable? Or is M&A the best way to go? What are the new trends in VC exit strategies? This panel looks at the struggles and successes in IPOs in 2006, lessons learned, and what to expect in the coming years as the fickle IPO window opens and closes.
Moderators
- Kevin T. Collins; Shareholder, HellerEhrman LLP
Panelists
- Matthew Geller, Ph.D.; Head of Healthcare Investment Banking, Senior Managing Director, Investment Banking, Acumen BioFin, a division of Rodman & Renshaw, LLC
- Glenn Kazo; Chief Business Officer, ActivBiotics, Inc.
- Michael Lytton; General Partner, Oxford Bioscience Partners
- Ron Cohen; President & CEO, Acorda Therapeutics, Inc.